

FUMAPHARM (BG12) MONTHLY ADCI  
MS  
June 06



**Phase 3 Studies: 109-MS-301 and 109-MS-302**

**Accomplishments**

European Scientific Advice meetings held in Sweden, Netherlands, UK and Spain. All agencies agreed on proposed primary endpoint of proportion relapsing.

